Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial
Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
BBY | BBY 13cent valuation buy rating | 24/06/14 | 0 | 2.3K | |||
|
|||||||
BBY | Ann: Removal from Official List at close 31/12/20 | 31/12/08 | 0 | 2.2K | |||
|
|||||||
BBY | and bbi...up and down autobots | 03/12/08 | 1 | 2.7K | |||
|
See All Discussions